Menopur (Menotrophin)

Menotropin provides both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. FSH drives growth of ovarian follicles and estrogen synthesis, while LH supports steroid production, ovulation, and, in males, testosterone synthesis by Leydig cells, thereby enhancing reproductive potential.

The dose of Menopur is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s clinical response, ovarian monitoring results, and the specific assisted‑reproduction protocol being used.

Menopur is not indicated for use during pregnancy, and its safety for the mother or fetus has not been established. Breastfeeding considerations should be discussed with a healthcare professional, as the drug may affect milk production or infant exposure.

To order Menopur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Menopur is a purified human menopausal gonadotropin containing both FSH and LH activity, whereas many newer agents are recombinant FSH only. The combined activity can be advantageous for certain protocols, but dosing may differ and some clinicians prefer recombinant products for their consistency and lower risk of antibody formation.

Menopur should be stored at 2‑8 °C in a refrigerator, protected from light. It must not be frozen or shaken. After reconstitution, the solution should be used promptly according to the prescribing information and any remaining product discarded if not used within the recommended time.

Menopur is supplied as a sterile injectable solution for intramuscular or subcutaneous injection. The vial is reconstituted with the appropriate diluent, and the dose is drawn into a sterile syringe. Administration technique and injection site are determined by the treating physician.

The most serious risks associated with Menopur include ovarian hyperstimulation syndrome (OHSS), which can be severe and life‑threatening, multiple gestation pregnancies, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for abdominal pain, rapid weight gain, shortness of breath, or signs of allergic response.

Menopur is contraindicated in individuals with known hypersensitivity to menotropin or any component of the formulation, in patients with ovarian cysts or tumors, in those with uncontrolled thyroid disease, and in patients with active hormone‑sensitive cancers. Use should also be avoided in pregnancy.